Comparisons between the GLP-1R agonists and other insulinotropic drugs such as insulin glargine or the sulphonylurea, glimepiride, have demonstrated that, in addition to better reduction in HbA1c, patients using GLP-1R agonists experience a significantly lower incidence of overall hypoglycaemia, [18,20,23,42] consistent with the glucose-dependent nature of GLP-1R agonists. This evidence concerns the gene GLP1R and Hypoglycemia.